Skip to main content

Table 1 Clinical characteristics of the patients

From: The impact of pharmacological thromboprophylaxis and disease-stage on postoperative bleeding following colorectal cancer surgery

 

Postoperative bleeding (−), N = 207

Postoperative bleeding (+), N = 11

p value

Backgrounds of patients

 Age (years)

69 (61–74)

65 (60–74)

0.6270

 Gender (male:female)

122:85

8:3

0.3524

 Height (cm)

159.8 (152.7–166.6)

166.0 (154.1–170.8)

0.3006

 Weight (kg)

54.7 (49.7–62.8)

64.0 (51.9–70.3)

0.0958

 ASA-PS classification (1:2:3)

80:122:5

4:6:1

0.5673

Preoperative laboratory examinations

 Platelet (104/mm3)

23.3 (18.3–26.9)

25.7 (21.5–28.6)

0.1377

 eGFR

73.3 (61.3–85.8)

69.3 (64.2–78.3)

0.8283

 Serum ALT (IU/L)

17 (11–24)

20 (14–26)

0.2967

 Serum T-Bil (IU/L)

0.62 (0.50–0.92)

0.74 (0.46–0.77)

0.6609

 D-dimer (μ/mL)

0.55 (0.3–1.1)

0.4 (0.3–0.7)

0.5690

 CEA (ng/mL)

5.3 (2.8–11.8)

4.8 (2.5–11.3)

0.8202

 CA19-9 (U/mL)

14 (8–23)

21 (10–40)

0.3140

Preoperative comorbidities

 Number of comorbidities

(4:3:2:1:0)

1:3:15:59:129

0:1:0:3:7

0.4854

 Hypertension

162

4

 

 Diabetes mellitus

29

2

 

 Cerebrovascular disease

7

1

 

 Ischemic heart disease

2

0

 

 Respiratory disease

9

0

 

Surgical and tumor characteristics

 Approach (open:laparoscopic)

80:127

2:9

0.1505

 Blood loss (g)

162 (50–403)

170 (50–229)

0.8022

 Duration of surgery

   

  Open (min)

223 (181–408)

379 (162–597)

0.7841

  Laparoscopic (min)

284 (227–342)

237 (216–313)

0.3000

 Use of epidural anesthesia, n (%)

189 (91.3%)

10 (90.9%)

0.9641

 Type of anticoagulants

(fondaparinux:enoxaparin)

60:147

7:4

0.0374

 Tumor location

(Rt colon:Lt colon:Rectum)

58:57:92

4:2:5

0.8280

 TNM classification

(stage 0:I:II:III:IV)

11:51:52:58:35

1:6:1:0:3

0.0267

  1. Data was presented as median (25th–75th percentile) and number (%). BMI body mass index, ASA-PS American Society of Anesthesiologists—physical status, eGFR estimated glomerular filtration rate, ALT alanine aminotransferase, T-Bil total-bilirubin, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, TNM classification UICC classification ver.7 Staging for adenocarcinoma